Serum Levels of Sodium Valproate in Patients Suffering from Bipolar Disorders: Comparing Acute and Maintenance Phases of Mania

Abstract

Objectives:

Bipolar disorders (BD) are characterized by episodes of mania and depression. There is evidence that states of psychiatric disorders impact on neurotransmitters, endocrine system and membrane transport and, therefore, it is possible that specific phases of BD differentially influence the pharmacokinetics of some drugs. The aim of the present study was to investigate the drug-disease interaction between sodium valproate, one of the major drugs used in the treatment of bipolar disorder, and acute versus maintenance states of manic episodes.

Method:

37 patients (mean age±SD=37.54±11.27 years; 23 males, 14 females) suffering from bipolar disorder completed the study. Blood samples were taken during both acute and maintenance states.

Results:

Neither the trough concentration (p=0.567) nor the internal clearances (p=0.729) of sodium valproate in the acute phase of mania differed statistically or descriptively from those in the maintenance phase. Marginally significant phase by gender interactions were observed.

Conclusion:

No significant effect of the acute phase of mania was observed in bipolar patients and no relationship could be found between drug pharmacokinetics and disease phase. This may be explained by specific pharmacokinetic features of the drug such as low extraction ratio values. However, phase by gender interactions indicate possible gender-related issues.

Key words

sodium valproate - bipolar disorder - drug-disease interaction - pharmacokinetics

• References

• 1 American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4 ed. Washington, DC: Authors; 2000
• 2 Merikangas KR, Jin R, He JP et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241-251
• 3 Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008; 20: 131-137
• 4 Allen MH, Hirschfeld RM, Wozniak PJ et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272-275
• 5 Lacy CF, Armstrong LL, Goldman MP et al. Drug Information Handbook 2006-2007. Washington, DC: The American Pharmaceutical Association; 2006
• 6 Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9: 199-216
• 7 Lagace DC, O’Brien T, Gurvich N, Nachtigal MW, Klein PS. Valproic acid: how it works. Or not. Clin Neuroscie Res 2004; 4: 215-225
• 8 Akhondzadeh S, Mohajari H, Reza Mohammadi M et al. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. BMC Psychiatry 2003; 3: 7
• 9 Daneshtalab N, Lewanczuk RZ, Russell AS et al. Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis. J Clin Pharmacol 2006; 46: 1344-1355
• 10 Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response. J Pharm Pharm Sci 2006; 9: 292-306
• 11 Sanaee F, Clements JD, Waugh AW et al. Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol 2011; 72: 787-797
• 12 DiPiro JT, Talbert RL, Yee GC et al. Pharmacotherapy: a pathophysiological approach. 4 ed. Stamford (CT): Appleton and Lange; 1999
• 13 Mohammadpour AH, Ghaeli P, Sadray S et al. Comparison of carbamazepine clearance between epileptic patients and patients with acute mania. Daru 2004; 12: 141-145
• 14 Kamalinia G, Rouini MR, Ghaeli P et al. N-(1-Naphthyl)ethylenediamine, a new UV labeling reagent used for LC determination of valproic acid in human plasma. Chromatographia 2009; 70: 569-573
• 15 Berwaerts J, Melkote R, Nuamah I et al. randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012; 138: 247-258
• 16 Pugh MJ, Starner CI, Amuan ME et al. Exposure to potentially harmful drug-disease interactions in older community-dwelling veterans based on the Healthcare Effectiveness Data and Information Set quality measure: who is at risk?. J Am Geriatr Soc 2011; 59: 1673-1678
• 17 Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm 2006; 12: 640-648
• 18 Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185-191
• 19 Sergi G, De Rui M, Sarti S et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?. Drugs Aging 2011; 28: 509-518
• 20 http://www.tevausa.com/assets/base/products/pi/Divalproex_PI_12-2007.pdf (accessed May 23, 2012